Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Perdiguero B et al. – This review analyzes current knowledge on the VACV genes encoding proteins acting as decoy receptors to block the activity of type I and type II IFNs, targeting cytokines and chemokines, and antagonizing intracellular signaling pathways (pattern recognition receptors [PRRs] signaling). The molecular dissection of how VACV prevents the IFN response is providing important insights on our understanding of antiviral action and immune surveillance.

Related Articles

Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma
European Journal of Cancer, 10/29/09    Relevance Score: 88%

MicroRNA expression, survival, and response to Interferon in liver cancer
New England Journal of Medicine, 10/08/09    Relevance Score: 88%

Human Papillomaviruses and the Interferon Response
Journal of Interferon & Cytokine Research, 10/07/09    Relevance Score: 88%

Interferon-gamma–Dependent Infiltration of Human T Cells into Neuroblastoma Tumors In vivo
Clinical Cancer Research, 10/19/09    Relevance Score: 87%

Enhancement of Chemokine Expression by Interferon Beta Therapy in Patients With Multiple Sclerosis
Archives of Neurology, 10/14/09    Relevance Score: 87%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address